Lenvatinib in Advanced Radioiodine-Refractory Thyroid Cancer - A Retrospective Analysis of the Swiss Lenvatinib Named Patient Program

Conclusions: Our results show that lenvatinib has reasonable clinical activity in unselected patients with RAI-refractory thyroid cancer with nearly two-third of patients showing clinical benefit. The toxicity profile of lenvatinib is manageable.

Source: Journal of Cancer - June 20, 2018 Category: Cancer & Oncology Authors: Catharina Balmelli, Nikola Railic, Marco Siano, Kristin Feuerlein, Richard Cathomas, Valerie Cristina, Christiane G ü thner, Stefan Zimmermann, Sabine Weidner, Miklos Pless, Frank Stenner, Sacha I. Rothschild Tags: Research Paper Source Type: research